These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 16307499)

  • 1. Rabeprazole: the role of proton pump inhibitors in Helicobacter pylori eradication.
    Sharara AI
    Expert Rev Anti Infect Ther; 2005 Dec; 3(6):863-70. PubMed ID: 16307499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan.
    Miki I; Aoyama N; Sakai T; Shirasaka D; Wambura CM; Maekawa S; Kuroda K; Tamura T; Kita T; Sakaeda T; Okumura K; Kasuga M
    Eur J Gastroenterol Hepatol; 2003 Jan; 15(1):27-33. PubMed ID: 12544691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review article: relationship between the metabolism and efficacy of proton pump inhibitors--focus on rabeprazole.
    Horn J
    Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 6():11-9. PubMed ID: 15496214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan.
    Dojo M; Azuma T; Saito T; Ohtani M; Muramatsu A; Kuriyama M
    Dig Liver Dis; 2001 Nov; 33(8):671-5. PubMed ID: 11785712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The importance of the level of metronidazole resistance for the success of Helicobacter pylori eradication.
    Wheeldon TU; Granström M; Hoang TT; Phuncarg DC; Nilsson LE; Sörberg M
    Aliment Pharmacol Ther; 2004 Jun; 19(12):1315-21. PubMed ID: 15191514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection.
    Take S; Mizuno M; Ishiki K; Nagahara Y; Yoshida T; Inaba T; Yamamoto K; Okada H; Yokota K; Oguma K; Shiratori Y
    Am J Gastroenterol; 2003 Nov; 98(11):2403-8. PubMed ID: 14638340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis.
    Zhao F; Wang J; Yang Y; Wang X; Shi R; Xu Z; Huang Z; Zhang G
    Helicobacter; 2008 Dec; 13(6):532-41. PubMed ID: 19166419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review article: the pharmacology of rabeprazole.
    Williams MP; Pounder RE
    Aliment Pharmacol Ther; 1999 Aug; 13 Suppl 3():3-10. PubMed ID: 10491723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Proton pump inhibitors: Rabeprazole].
    Yoshino J
    Nihon Rinsho; 2002 Feb; 60 Suppl 2():645-9. PubMed ID: 11979863
    [No Abstract]   [Full Text] [Related]  

  • 10. Inhibitory action of a novel proton pump inhibitor, rabeprazole, and its thioether derivative against the growth and motility of clarithromycin-resistant Helicobacter pylori.
    Ohara T; Goshi S; Taneike I; Tamura Y; Zhang HM; Yamamoto T
    Helicobacter; 2001 Jun; 6(2):125-9. PubMed ID: 11422467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Seven versus ten days of rabeprazole triple therapy for Helicobacter pylori eradication: a multicenter randomized trial.
    Calvet X; Ducons J; Bujanda L; Bory F; Montserrat A; Gisbert JP;
    Am J Gastroenterol; 2005 Aug; 100(8):1696-701. PubMed ID: 16086704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do some patients with Helicobacter pylori infection benefit from an extension to 2 weeks of a proton pump inhibitor-based triple eradication therapy?
    Maconi G; Parente F; Russo A; Vago L; Imbesi V; Bianchi Porro G
    Am J Gastroenterol; 2001 Feb; 96(2):359-66. PubMed ID: 11232676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review article: rabeprazole-based therapy in Helicobacter pylori eradication.
    Barth J; Hahne W
    Aliment Pharmacol Ther; 2002 Mar; 16 Suppl 1():31-3. PubMed ID: 11849125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rabeprazole containing triple therapy to eradicate Helicobacter pylori infection on the Texas-Mexican border.
    Cardenas VM; Graham DY; El-Zimaity HM; Opekun AR; Campos A; Chavez A; Guerrero L
    Aliment Pharmacol Ther; 2006 Jan; 23(2):295-301. PubMed ID: 16393310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Masking of 13C urea breath test by proton pump inhibitors is dependent on type of medication: comparison between omeprazole, pantoprazole, lansoprazole and esomeprazole.
    Levine A; Shevah O; Shabat-Sehayek V; Aeed H; Boaz M; Moss SF; Niv Y; Avni Y; Shirin H
    Aliment Pharmacol Ther; 2004 Jul; 20(1):117-22. PubMed ID: 15225178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.
    Li XQ; Andersson TB; Ahlström M; Weidolf L
    Drug Metab Dispos; 2004 Aug; 32(8):821-7. PubMed ID: 15258107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Are proton pump inhibitors superior to H2 receptor antagonists within the scope of H. pylori eradication therapy? Meta analysis of current parallel group comparisons].
    Holtmann G; Layer P; Goebell H
    Z Gastroenterol; 1996 May; 34(5):267-72. PubMed ID: 8686357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eradication of Helicobacter pylori increases nocturnal intragastric acidity during dosing with rabeprazole, omeprazole, lansoprazole and placebo.
    Williams MP; Usselmann B; Chilton A; Sercombe J; Nwokolo CU; Pounder RE
    Aliment Pharmacol Ther; 2003 Mar; 17(6):775-83. PubMed ID: 12641499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of a triple therapy with rabeprazole, amoxicillin, and faropenem as second-line treatment after failure of initial Helicobacter pylori eradication therapy.
    Togawa J; Inamori M; Fujisawa N; Takahashi H; Yoneda M; Kawamura H; Abe Y; Kirikoshi H; Kobayashi N; Sakaguchi T; Takamura T; Nakajima A; Ueno N; Sekihara H
    Hepatogastroenterology; 2005; 52(62):645-8. PubMed ID: 15816496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-analysis: comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication.
    Vergara M; Vallve M; Gisbert JP; Calvet X
    Aliment Pharmacol Ther; 2003 Sep; 18(6):647-54. PubMed ID: 12969092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.